重组活化凝血因子Ⅶ对脑出血的疗效

摘要

Objective To investigate the curative effect of recombinant activated clotting factor Ⅶ on treating patients with cerebral hemorrhage.Methods 80 patients with cerebral hemorrhage from February 2013 to February 2014 were divided into control group (n=40, treated with conventional method plus dicynone) and observation group (n=40, treated with conven‐tional method, dicynone plus rFⅦa). The curative effects of two groups before treatment, 24h, 72h and 1month after treat‐ment were compared.Results The hematoma volumes of observation group (24.5mL ± 8.3mL, 30.1mL ± 8.8mL) at 24h and 48h after treatment was lower than these of control group (26.6mL ± 8.5mL, 34.3mL ± 9.1mL). The NIHSS of observation group (7.1 ± 2.4) was that of control group (8.7 ± 2.5). The ADL score and effective rate of observation group (62.9 ± 16.8, 92.5% ) were these of control group (49.9 ± 17.0, 72.5% ), which had significant difference (P<0.05).Conclusion Early application of rFⅦa for patients with cerebral hemorrhage can inhibit hematoma enlargement and increase clinical effect, which can improve neurological function and activity ability of daily living.%目的：探析脑出血患者早期采用重组活化凝血因子Ⅶ（rFⅦa）止血的疗效。方法入选我院2013‐02—2014‐02脑出血患者80例，根据入院先后顺序分为2组各40例，发病3 h时内，对照组在常规治疗的基础上加用止血敏，观察组在常规治疗的基础上静脉注射r FⅦa ，比较2组患者治疗前、治疗后24 h、48 h血肿情况，1个月后治疗效果等情况。结果观察组用药后24 h血肿体积（24.5±8.3）m L显著低于对照组（30.1±8.8）m L ，用药后48 h血肿体积（26.6±8.5）m L也显著低于对照组（34.3±9.1）mL ，观察组治疗1个月后NIHSS评分（7.1±2.4）分显著低于对照组（8.7±2.5）分，ADL评分（62.9±16.8）分显著高于对照组（49.9±17.0）分，观察组临床有效率92.5％（37／40）显著高于对照组72.5％（29／40），差异均具有统计学意义（均 P＜0.05）。结论脑出血患者发病早期采用r FⅦa止血有助于抑制血肿增大，从而提高临床疗效，全面改善神经功能及日常生活活动能力。